Evidence map›Paper›PMID 32516450›Full record

ArticleInternational journal of dermatology2020

Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study.

Suzette M Arias-Mejias, Enrica Quattrocchi, Dennie Tempel, Mark Luna-Vargas, Jeff Chen, Dennis H Murphree, Sandra Gjorgova Gjeorgjievski, Julia S Lehman, Alina G Bridges, Jvalini Dwarkasing and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Suzette M Arias-MejiasDepartment of Dermatology, Mayo Clinic, Rochester, MN, USA.
Enrica QuattrocchiDepartment of Dermatology, Mayo Clinic, Rochester, MN, USA.
Dennie TempelSkylineDx B.V., Rotterdam, the Netherlands.
Mark Luna-VargasSkylineDx B.V., Rotterdam, the Netherlands.
Jeff ChenSkylineDx B.V., Rotterdam, the Netherlands.
Dennis H MurphreeDivision of Digital Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0002-7800-455X
Sandra Gjorgova GjeorgjievskiDivision of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.
Julia S LehmanDivision of Dermatopathology and Cutaneous Immunopathology, Mayo Clinic, Rochester, MN, USA.
Alina G BridgesDivision of Dermatopathology and Cutaneous Immunopathology, Mayo Clinic, Rochester, MN, USA.
Jvalini DwarkasingSkylineDx B.V., Rotterdam, the Netherlands.
Alexander MevesDepartment of Dermatology, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0001-7462-8288

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Precision Medicine by Targeting Cell Adhesion in MelanomaK08CA215105 · NCI · MAYO CLINIC ROCHESTER · PI MEVES, ALEXANDER · 2017 to 2021
$854k
NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1TR000135NCI NIH HHS CA215105NCI NIH HHS K08 CA215105
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MelanomaSkin NeoplasmsGene ExpressionHumansPilot ProjectsPrognosisRisk Assessment

Identifiers

PMID32516450
PMCPMC7687092

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.